refills.com tirzepatide Non Member Prescription Refills title *Note: This is a

Two leading investigational therapies are attracting significant attention: MariTide (Maridebart Cafraglutide / AMG 133) Amgen Novel GLP-1 receptor agonist + GIP receptor antagonist Up to ~20% mean weight loss at 52 weeks in Phase 2 studies No weight-loss plateau observed at one year Currently advancing through the Phase 3 MARITIME program Potential for monthly or even less frequent administration PF-08653944 (Berobenatide) -Pfizer Ultra-long-acting GLP-1 receptor agonist Up to 12.3% placebo-adjusted weight loss at 28 weeks in Phase 2b Continued weight reduction after transition to monthly maintenance dosing No plateau observed at the 28-week analysis Designed to simplify long-term obesity management through monthly dosing Key Takeaway While MariTide currently leads in weight-loss efficacy, Pfizers Berobenatide highlights the potential of a streamlined, pure GLP-1 approach optimized for monthly maintenance and adherence

No insurance is required, and the medication is HSA/FSA eligible, making it accessible for most patients

Understanding PlexusDx Pricing: Flat Rates, Not Dose-Based Tiers Many GLP-1 programs charge per-dose or use escalating price tiers as patients increase their strength, creating financial disincentives to optimal treatment

Youtheory Shaklee Corporation Ora Organic Supergut Lemme Ritual Thorne HealthTech Designs for Health Lumen Needed Glanbia plc Abbott Laboratories Nestl Health Science Danone S.A